Premium
TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T‐CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
Author(s) -
Witzig T.,
Sokol L.,
Kim W.,
Foss F.,
Jacobsen E.,
Cruz Vincente F.,
Caballero D.,
Advani R.,
Roncero Vidal J.M.,
MarinNiebla A.,
Rodriguez Izquierdo A.,
Ovarrete R.,
Terol M.J.,
DomingoDomenech E.,
Rodriguez M.,
Piris M.A.,
Bolognese J.,
Janes M.R.,
Burrows F.,
Kessler L.,
Mishra V.,
Curry R.,
Kurman M.,
Scholz C.,
Gualberto A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.32_2629
Subject(s) - medicine , angioimmunoblastic t cell lymphoma , oncology , clinical endpoint , peripheral t cell lymphoma , refractory (planetary science) , rash , bone marrow , lymphoma , phases of clinical research , clinical trial , t cell , immune system , immunology , physics , astrobiology